Optimized Subretinal Injection Technique for Gene Therapy Approaches.

[1]  Kathleen A. Marshall,et al.  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial , 2017, The Lancet.

[2]  N. Tanimoto,et al.  AAV-Mediated Gene Supplementation Therapy in Achromatopsia Type 2: Preclinical Data on Therapeutic Time Window and Long-Term Effects , 2017, Front. Neurosci..

[3]  M. Biel,et al.  Gene therapy for achromatopsia , 2017, The journal of gene medicine.

[4]  M. Biel,et al.  Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[5]  Balaji Balakrishnan,et al.  Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. , 2014, Current gene therapy.

[6]  M. Biel,et al.  Gene replacement therapy for retinal CNG channelopathies , 2013, Molecular Genetics and Genomics.

[7]  Paolo Melillo,et al.  Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. , 2013, Ophthalmology.

[8]  N. Tanimoto,et al.  Gene therapy restores vision and delays degeneration in the CNGB1(-/-) mouse model of retinitis pigmentosa. , 2012, Human molecular genetics.

[9]  N. Tanimoto,et al.  Restoration of cone vision in the CNGA3-/- mouse model of congenital complete lack of cone photoreceptor function. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  W. Berger,et al.  The molecular basis of human retinal and vitreoretinal diseases , 2010, Progress in Retinal and Eye Research.

[11]  A. D. den Hollander,et al.  Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. , 2010, The Journal of clinical investigation.

[12]  Karl Deisseroth,et al.  Genetic Reactivation of Cone Photoreceptors Restores Visual Responses in Retinitis Pigmentosa , 2010, Science.

[13]  C. Guihal,et al.  Regulation of retinal function but nonrescue of vision in RPE65-deficient dogs treated with doxycycline-regulatable AAV vectors. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  U. Wolfrum,et al.  Adeno-associated virus-mediated rhodopsin replacement provides therapeutic benefit in mice with a targeted disruption of the rhodopsin gene. , 2010, Human gene therapy.

[15]  A. J. Roman,et al.  Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. , 2009, Human gene therapy.

[16]  W. Hauswirth,et al.  High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  J. Boatright,et al.  Technical Brief: Subretinal injection and electroporation into adult mouse eyes , 2008, Molecular vision.

[18]  W. Hauswirth,et al.  Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. , 2008, Human gene therapy.

[19]  Edwin M Stone,et al.  Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics , 2008, Proceedings of the National Academy of Sciences.

[20]  N. Muzyczka,et al.  Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses , 2008, Proceedings of the National Academy of Sciences.

[21]  R. Ali,et al.  AAV-mediated gene therapy for retinal disorders: from mouse to man , 2008, Gene Therapy.

[22]  W. Hauswirth,et al.  Effect of late-stage therapy on disease progression in AAV-mediated rescue of photoreceptor cells in the retinoschisin-deficient mouse. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  Kathleen A. Marshall,et al.  Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[24]  J. Bennett,et al.  Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. , 2008, The Journal of clinical investigation.

[25]  E. Surace,et al.  Versatility of AAV vectors for retinal gene transfer , 2008, Vision Research.

[26]  W. Hauswirth,et al.  Comparative analysis of in vivo and in vitro AAV vector transduction in the neonatal mouse retina: Effects of serotype and site of administration , 2008, Vision Research.

[27]  M. Seeliger,et al.  Long‐term evaluation of retinal function in Prph2Rd2/Rd2 mice following AAV‐mediated gene replacement therapy , 2003, The journal of gene medicine.

[28]  D. Charteris,et al.  Stable rAAV-mediated transduction of rod and cone photoreceptors in the canine retina , 2003, Gene Therapy.

[29]  T. Hughes,et al.  Transgenic expression of the jellyfish green fluorescent protein in the cone photoreceptors of the mouse , 2001, Visual Neuroscience.

[30]  A. Timmers,et al.  Subretinal injections in rodent eyes: effects on electrophysiology and histology of rat retina. , 2001, Molecular vision.

[31]  J. Flannery,et al.  Advances in AAV vector development for gene therapy in the retina. , 2014, Advances in experimental medicine and biology.

[32]  H. Weng,et al.  Supplementary Appendix , 2007 .

[33]  F. Liang,et al.  Intraocular delivery of recombinant virus. , 2001, Methods in molecular medicine.

[34]  C. Cepko,et al.  Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. , 1987, Proceedings of the National Academy of Sciences of the United States of America.